ProhibitedBinding ruleGBOriginal is EnglishOfficial-source import checked

Hyoscyamine, its salts and derivatives

The consolidated GB Cosmetics Regulation lists this record in Annex II.

Regulatory decision and full conditions

Status
Prohibited
Legal role
Binding rule
Regulatory summary
The consolidated GB Cosmetics Regulation lists this record in Annex II.
Conditions and restrictions
A prohibition entry may contain no separate condition text because the regulatory outcome is the prohibition itself. Open the cited source and apply the market-wide requirements below.

Substance identity

Official source name
Hyoscyamine, its salts and derivatives
CAS
101-31-5
EC
202-933-0
Identity mapping
standalone:official_gb_annex

Cross-market snapshot for this identity

Exact linked records currently present in this site. An absent market means no imported exact match, not permission to use the substance.

10 market datasets
PubChem 2D chemical structure for CAS 101-31-5
CAS 101-31-5PubChem CID 154417

Verified chemistry for CAS 101-31-5

Benzeneacetic acid, alpha-(hydroxymethyl)-, (3-endo)-8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester, (alphaS)-

(S)-atropine is an atropine with a 2S-configuration. It is functionally related to a (S)-tropic acid. It is a conjugate base of a (S)-atropinium. ChEBI

IUPAC name
[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] (2S)-3-hydroxy-2-phenylpropanoate
Molecular formula
C17H23NO3
Molecular weight
289.4 g/mol
Exact mass
289.16779360 Da
Monoisotopic mass
289.16779360 Da
XLogP3
1.8
Topological polar surface area
49.8 Ų
Molecular complexity
353.0
Formal charge
0
Hydrogen-bond donors
1
Hydrogen-bond acceptors
4
Rotatable bonds
5
Heavy atoms
21
Covalent units
1

Names and synonyms reported to PubChem

Benzeneacetic acid, .alpha.-(hydroxymethyl)-, (3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester, (.alpha.S)-Benzeneacetic acid, alpha-(hydroxymethyl)-, (3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester, (alphaS)-BENZENEACETIC ACID, .ALPHA.-(HYDROXYMETHYL)-, (3-ENDO)-8-METHYL-8-AZABICYCLO(3.2.1)OCT-3-YL ESTER, (.ALPHA.S)-RefChem:562898Benzeneacetic acid, .alpha.-(hydroxymethyl)-, (3-endo)-8-methyl-8-azabicyclo3.2.1oct-3-yl ester, (.alpha.S)-Benzeneacetic acid, alpha-(hydroxymethyl)-, (3-endo)-8-methyl-8-azabicyclo3.2.1oct-3-yl ester, (alphaS)-hyoscyamineL-Hyoscyamine
16 more reported names
Daturine(-)-HyoscyamineDuboisine(-)-AtropineL-Tropine tropate(S)-(-)-HyoscyamineCystospazl-Atropine(S)-AtropineHyoscyamine (L)LevsinBellafolineHyoscyaminumAtropine, (s)-ENDO-ATROPINETropine, (-)-tropate
External database identifiers
Advanced structure statistics
Defined atom stereocentres
3
Undefined atom stereocentres
0
Defined bond stereocentres
0
Undefined bond stereocentres
0
3D pharmacophore features
6
3D rings
2
3D hydrophobes
0
3D acceptor features
2
3D donor features
1
3D anionic centres
0
3D cationic centres
1
3D conformers
10
Effective 3D rotors
6.2
Machine-readable structure identifiers
SMILES
CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)[C@H](CO)C3=CC=CC=C3
InChI
InChI=1S/C17H23NO3/c1-18-13-7-8-14(18)10-15(9-13)21-17(20)16(11-19)12-5-3-2-4-6-12/h2-6,13-16,19H,7-11H2,1H3/t13-,14+,15?,16-/m1/s1
InChIKey
RKUNBYITZUJHSG-VFSICIBPSA-N

Evidence from additional scientific databases

EMBL-EBI ChEBI
Exact identifier matchCHEBI:17486

(S)-atropine

An atropine with a 2S-configuration.

Formula
C17H23NO3
Average mass
289.375 g/mol
Monoisotopic mass
289.16779 Da
Formal charge
0
  • tropan-3α-yl 3-hydroxy-2-phenylpropanoate — is a (CHEBI:78734)
  • (S)-tropic acid — has functional parent (CHEBI:30766)
  • tropan-3α-yl 3-hydroxy-2-phenylpropanoate — is a (CHEBI:78734)
  • (S)-atropinium — is conjugate base of (CHEBI:58164)
Additional curated names
(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl (2S)-3-hydroxy-2-phenylpropanoatetropan-3alpha-yl (2S)-3-hydroxy-2-phenylpropanoate[3(S)-endo]-alpha-(hydroxymethyl)benzeneacetic acid 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester(-)-atropineDaturineDuboisinel-hyoscyamine(-)-hyoscyaminehyoscyamine(S)-(-)-hyoscyamineL-HyoscyamineL-Tropine tropatetropine, (-)-tropate
Cross-references from this source
  • CAS: 101-31-5 — KEGG COMPOUND
  • CAS: 101-31-5 — ChemIDplus
  • CAS: 101-31-5 — NIST Chemistry WebBook
  • MANUAL_X_REF: 1402 — DrugCentral
  • MANUAL_X_REF: C00002293 — KNApSAcK
  • MANUAL_X_REF: C02046 — KEGG COMPOUND
  • MANUAL_X_REF: D00147 — KEGG DRUG
  • MANUAL_X_REF: DB00424 — DrugBank
  • MANUAL_X_REF: OIN — PDBeChem
  • REGISTRY_NUMBER: 91259 — Reaxys

Mapped by: Exact CAS cross-reference in the ChEBI compound record. Source updated: 2017-02-22. Retrieved: 2026-08-31. Open source record

NIH PubChem PUG-View
Exact identifier match154417

Attributed physical-property, hazard, environmental and use annotations.

Mapped by: Existing checksum-valid CAS to unique PubChem CID match. Retrieved: 2026-08-31. Open source record

Scientific classifications and hazard annotations provide context and do not replace the market-specific regulatory decision shown above.

Additional source coverage and match status
SourceResultChecked
EMBL-EBI ChEBIExact match2026-08-31
NIH PubChem PUG-ViewExact match2026-08-31

A recorded no-match is useful evidence that the source was checked; it is not a claim that the substance does not exist elsewhere.

Retrieved from NIH PubChem on 2026-08-31 by checksum-valid CAS matching. Chemical properties do not replace the regulatory decision on this page.

Official source and provenance

Registered source
Great Britain Cosmetics Regulation — consolidated Annexes II–VI and amendments
Source reference
GB Cosmetics Regulation, Annex II, entry 210
Source record ID
II-210
Source version
2026-08-15
Source language
English
Translation status
Original is English
Effective date
2026-08-15
Source updated
2026-08-19
Snapshot checked
2026-08-30 04:51 UTC
Validation method
legislation.gov.uk XML table parse; {'II': 1758, 'III': 326, 'IV': 154, 'V': 57, 'VI': 34}
SHA-256
e3a386d950f54c6e7a7f9e784d1bd46e52de725137e89d5630709824475215d8

Registered dataset notes

Dataset coverage
Complete consolidated GB Annexes II–VI, with later amendments versioned separately
Authority note
Binding GB schedules and versioned amendments to retained Regulation 1223/2009; applies to England, Wales and Scotland, not Northern Ireland
Source licence
Open Government Licence v3.0 / Crown copyright
Attribution
Contains public sector information licensed under the Open Government Licence v3.0.

How this record fits the market dataset

2329
current Great Britain records
1758
records marked Prohibited
2329
records from this source version
2015
market records with CAS identity

Status distribution

Condition text is present on 517 of 2329 current records. An empty condition field is interpreted according to the record type above; it is never converted into an unrestricted-use claim.

Great Britain market context

Complete consolidated annex dataset

Coverage version: GB retained Regulation 1223/2009 schedules, effective 15 August 2026

Current consolidated Annexes II–VI for England, Scotland and Wales.

Verification checklist

  1. Confirm INCI/CAS/EC identity.
  2. Review every current GB Annex II–VI match.
  3. Check commencement dates and later statutory instruments.
  4. Verify SCPN, responsible-person, safety-report and labelling duties.

Official market sources

Verification workflow and record completeness

Before using this result in a compliance decision

  1. Confirm that “Hyoscyamine, its salts and derivatives” and every CAS/EC identifier refer to the material in your supplier specification.
  2. Confirm INCI/CAS/EC identity.
  3. Review every current GB Annex II–VI match.
  4. Check commencement dates and later statutory instruments.
  5. Verify SCPN, responsible-person, safety-report and labelling duties.
  6. Document the source version and recheck the regulator before manufacture, notification or market placement.

Fields available in this record

  • Official substance nameAvailable
  • CASAvailable
  • ECAvailable
  • Separate condition textNot present in source row
  • Effective dateAvailable
  • Snapshot hash and methodAvailable

Questions this page answers

This official record identifies the substance as prohibited for cosmetic use in the stated market scope. Do not rely on a formulation containing this identity until the cited source, effective date and exact substance match have been verified.

A prohibition entry may contain no separate condition text because the regulatory outcome is the prohibition itself. No annex match is not approval and does not cover Northern Ireland, which follows the applicable EU framework.

The record cites GB Cosmetics Regulation, Annex II, entry 210, source version 2026-08-15. Open the official source.

No. CAS helps resolve identity, but jurisdictions can classify the same substance differently and can apply different product scopes, limits, warnings and transition dates.

Stable citation

Hyoscyamine, its salts and derivatives. GB Cosmetics Regulation, Annex II, entry 210. Great Britain. Source version 2026-08-15. CosIng Checker regulatory record: https://cosingchecker.com/regulations/gb/records/4567/

Cite the regulator as the legal authority. This page is a structured evidence index and verification aid, not a substitute for the official text or professional legal assessment.

Interpretation and limits for Great Britain

This official record identifies the substance as prohibited for cosmetic use in the stated market scope.

Do not rely on a formulation containing this identity until the cited source, effective date and exact substance match have been verified.

How to interpret the legal role

The cited row forms part of a binding rule or legally incorporated list for this market.

Evidence on this page

  • Recorded outcome: Prohibited
  • Legal role: Binding rule
  • Source version: 2026-08-15
  • Effective date: 2026-08-15

What it does not prove

No annex match is not approval and does not cover Northern Ireland, which follows the applicable EU framework.

Further authoritative substance research

These sources can add identity, safety, exposure or hazard context. A link is not evidence that the database contains this exact substance, and none of these sources overrides the market decision above.

Cosmetic Ingredient Review safety assessments

Expert Panel conclusions, assessed ingredient groups, use conditions, dates and report documents

Independent expert review considered by FDA; not a government approval or binding market rule

Research this identity at the source

FDA Global Substance Registration System

UNII identifiers, preferred names, substance types, codes and public substance relationships

Identity registry only; UNII availability does not imply FDA review or approval

Research this identity at the source

ILO/WHO International Chemical Safety Cards

Hazards, symptoms, first aid, storage, incompatibilities and physical properties for covered chemicals

International occupational chemical-safety reference; not cosmetic-use approval

Research this identity at the source

Japan NITE-CHRIP

Chemical identity, Japanese and foreign legal lists, GHS hazards and exposure-related information

Chemical-management evidence; cosmetic status remains governed by the applicable MHLW standard and market rules

Research this identity at the source

NIOSH Pocket Guide to Chemical Hazards

REL, PEL, IDLH, properties, exposure routes, symptoms, target organs, first aid and measurement methods for covered workplace chemicals

US occupational-health guidance and limits; not a cosmetic ingredient decision

Research this identity at the source

OECD eChemPortal

Gateway to authority-owned physical-property, fate, ecotoxicity, toxicity, exposure and GHS records

Discovery gateway; each linked authority remains responsible for its data

Research this identity at the source

US EPA CompTox CTX APIs

API key required for import

DTXSID identity, experimental and predicted properties, toxicity, bioactivity, exposure and environmental data

Scientific and computational evidence; predictions must remain labelled and do not determine cosmetic legality

Research this identity at the source